These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20824236)

  • 1. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing among incretin-based therapies. Patient education and self-management.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incretin-based therapy for treating patients with type 2 diabetes].
    Jermendy G
    Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin physiology and its role in type 2 diabetes mellitus.
    Svec F
    J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
    Tibaldi JM
    Adv Ther; 2014 Mar; 31(3):289-317. PubMed ID: 24535623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incretin related agents for treatment of diabetes mellitus].
    Miyagawa J; Miuchi M; Nanba M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
    [No Abstract]   [Full Text] [Related]  

  • 13. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 14. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK; Lereun C; Wright D
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S5-9. PubMed ID: 20824239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
    Ahrén B
    Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.